Q1 2024 revenue was $8.8 million, which represents an 18% increase over Q1 2023Total installed base of 347 optical genome mapping (OGM) systems as of Q1 2024, which represents a 34% increase over Q1 2023Sold 8,249 nanochannel array flowcells in Q1 2024, which represents a 58% increase over the number of flowcells sold in Q1 2023Efforts to reduce cash burn and operating expense continued with the March 2024 announcement of expanded cost savings initiatives; since the initial cost savings initiative announced ...

Many investors abandon highly promising shares with little chance of failing. The phenomenon has been exacerbated by overdone fears about elevated interest rates. Short sellers often believe that elevated rates will crush indebted, money-losing firms, regardless of their potential. These short sellers put huge downward pressure on small companies that are still in the red and have some debt. As their stock prices sink, many other investors also avoid buying their shares. As a result, the stocks keep continu ...

Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology. Their joint endeavor aims to commercialize the first ever cytogenetic workflow that integrates OGM plus AI chromosome karyotype analysisDiagens will become an original equipment manufacturing (OEM) partner of ...

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 8,733,626 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 8,733,626 shares of its common stock at an offering price of $1.145 per share of common stock (or per common stock equivalent in lieu thereof) and accompanying warrant, in a registered direct ...

Nine scientific posters will illustrate the application of optical genome mapping (OGM) in cancer research areas including hematological malignancies, solid tumors, and applications in cell and gene therapy, cell manufacturing and bioprocessing quality controlBionano is introducing its new Stratys™ system for high throughput OGM to the cancer research communityBionano will preview VIA™ 7.1 software, an upcoming advancement to the Company's software for visualization, interpretation and reporting of OGM, nex ...

Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants David Holmes - Investor Relations Erik Holmlin - Chief Executive Officer Gulsen Kama - Chief Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Mark Massaro - BTIG Jeff Cohen - Ladenburg Thalmann Michael Okunewitch - Maxim Group Operator Good day and welcome to the Bionano Fourth Quarter and Full Year 2023 Earnings Conference Call. Today’s conference is being recorded. At ...

Q4 2023 revenue was $10.7 million, which represents a 30% increase over Q4 2022FY 2023 revenue was $36.1 million, which represents a 30% increase over FY 2022Reached installed base of 326 optical genome mapping (OGM) systems as of YE 2023; increase of 36% over the 240 installed systems as of YE 2022Sold 26,444 nanochannel array flowcells in FY 2023, which represents a 72% increase over the flowcells sold in FY 2022Conference call today, March 5, 2024 at 4:30 PM ET SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) ...

Table of Contents | --- | --- | --- | |------------|---------------------------------------------------------------------------------------------------------------------------|-------| | | | Page | | PART I | | | | Item 1. | Business | 8 | | Item 1A. | Risk Factors | 29 | | Item 1B. | Unresolved Staff Comments | 69 | | Item 1C. | Cybersecurity | 70 | | Item 2. | Properties | 72 | | Item 3. | Legal Proceedings | 72 | | Item 4. | Mine Safety Disclosures | 72 | | PART II | | | | Item 5. | Market for Registrant ...

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at TD Cowen’s 44th Annual Health Care Conference on March 6, 2024. Conference & Webcast Details Date:Wednesday, March 6th, 2024Time:12:50 p.m. to 1:20 p.m. ETPresenter:Erik Holmlin, PhD, CEO of BionanoWebcast:Link to Register A replay / recording of the session will be available following the conference through the Bionano w ...

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 5, 2024, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2023 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Tuesday, March 5th, 2024Time:4:30 p.m. ETParticipant Call Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/afaym86g/ Participa ...